Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Abraxis BioScience, Inc. (ABII)
|
Add to portfolio |
|
|
|
| Price: |
$76.67
| | Metrics |
| OS: |
40.4
|
M
| |
-9
|
% ROE
|
| Market cap: |
$3.1
|
B
| |
-20
|
% ROIC
|
|
Net cash:
|
$188
|
M
| |
$4.66
|
per share
|
|
EV:
|
$2.91
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$22.2
|
M
| |
131.1
|
x EV/EBITDA
|
|
EBIT
|
($77.0)
|
M
| |
|
|
| EPS |
($1.87)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 359.1 | 345.3 | 333.7 | 182.3 | 135.7 |
| Revenue growth | 4.0% | 3.5% | 83.1% | 34.4% | |
| Cost of goods sold | 63.7 | 39.1 | 34.5 | 21.2 | 24.1 |
| Gross profit | 295.4 | 306.2 | 299.2 | 161.1 | 111.6 |
| Gross margin | 82.3% | 88.7% | 89.7% | 88.4% | 82.3% |
| Selling, general and administrative | 200.7 | 221.4 | 233.3 | 119.5 | 69.2 |
| Research and development | 154.6 | 99.0 | 85.4 | 63.1 | 50.1 |
| EBITA | -57.9 | -172.2 | -15.7 | -18.0 | -5.6 |
| EBITA margin | -16.1% | -49.9% | -4.7% | -9.9% | -4.2% |
| Amortization of intangibles | 39.8 | 39.4 | 38.7 | 28.0 | 0.3 |
| EBIT | -97.7 | -211.6 | -54.4 | -46.0 | -5.9 |
| EBIT margin | -27.2% | -61.3% | -16.3% | -25.2% | -4.4% |
| Pre-tax income | -107.3 | -278.7 | -49.6 | -150.5 | -12.2 |
| Income taxes | -2.6 | -1.9 | -8.0 | -26.0 | 0.5 |
| Tax rate | 2.4% | 0.7% | 16.0% | 17.3% | |
| Net income | -104.8 | -276.8 | -41.6 | -124.6 | -12.7 |
| Net margin | -29.2% | -80.2% | -12.5% | -68.3% | -9.3% |
| |
| Diluted EPS | ($2.57) | ($6.91) | ($1.04) | ($3.11) | ($0.32) |
| Shares outstanding (diluted) | 40.8 | 40.1 | 40.0 | 40.0 | 39.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|